++
Less than 30% of melanoma develops from existing moles
++
Contact dermatitis is more likely to develop in patients with atopic dermatitis; an allergic or irritating contactant should be considered when acute weeping lesions are present.
+++
LICHEN SIMPLEX CHRONICUS (CIRCUMSCRIBED NEURODERMATITIS)
++
Dupilumab is a new medication for generalized disease in lichen simplex chronicus or prurigo nodularis, its related condition.
++
Guttate and plaque psoriasis are important diagnostic considerations, and biopsy can help differentiate these from pityriasis rosea.
++
Oral acyclovir may improve the appearance of the rash.
+++
SEBORRHEIC DERMATITIS
++
Seborrheic dermatitis is associated with inflammation due to Malassezia species.
+++
CUTANEOUS LUPUS ERYTHEMATOSUS
++
Patients with cutaneous lupus erythematosus should be examined and tested annually (with a complete blood count and urinalysis) to screen for early signs of systemic involvement.
+++
MISCELLANEOUS SCALING DERMATOSES
++
Fluorouracil cream is the most effective topical agent for field treatment of actinic keratosis. Imiquimod, ingenol mebutate, and photodynamic therapy are also effective.
++
Some allergens will transmit through latex gloves.
++
It may take 3 months or more for truncal acne to resolve with oral antibiotic treatment.
++
Side effects from isotretinoin that are almost universal are cheilitis, dry skin, and photosensitivity.
++
Most treatments target the papulopustular and cystic components. Only certain topical medications (brimonidine and oxymetazoline) and laser benefit erythema, with laser treatment having longer term benefit.
++
Ligelizumab is effective for chronic urticaria in early clinical trials.
++
Etanercept is emerging as a promising therapy for Stevens- Johnson syndrome/toxic epidermal necrolysis and is now the treatment of choice in some centers.
++
Topical or systemic JAK inhibitors (tofacitinib, ruxolitinib) may be effective in some patients with recalcitrant vitiligo, although response to therapy is not the rule.
++
Platelet rich plasma is an emerging therapy in androgenetic alopecia in women.